These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24999268)

  • 1. Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes.
    Abdelsaid M; Coucha M; Ergul A
    Transl Res; 2014 Nov; 164(5):424-32. PubMed ID: 24999268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
    Cushman WC; Bakris GL; White WB; Weber MA; Sica D; Roberts A; Lloyd E; Kupfer S
    Hypertension; 2012 Aug; 60(2):310-8. PubMed ID: 22710649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome.
    Kagota S; Maruyama-Fumoto K; Shimari M; McGuire JJ; Shinozuka K
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):501-509. PubMed ID: 31420755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.
    Matsumoto S; Shimabukuro M; Fukuda D; Soeki T; Yamakawa K; Masuzaki H; Sata M
    Cardiovasc Diabetol; 2014 Jan; 13():30. PubMed ID: 24485356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
    Bakris GL; Sica D; White WB; Cushman WC; Weber MA; Handley A; Song E; Kupfer S
    Am J Med; 2012 Dec; 125(12):1229.e1-1229.e10. PubMed ID: 22939358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome].
    Skibitskiy VV; Fendrikova AV; Sirotenko DV; Skibitskiy AV
    Kardiologiia; 2016 Oct; 56(10):35-40. PubMed ID: 28290893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
    Barrios V; Escobar C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azilsartan Improves Salt Sensitivity by Modulating the Proximal Tubular Na+-H+ Exchanger-3 in Mice.
    Hatanaka M; Kaimori JY; Yamamoto S; Matsui I; Hamano T; Takabatake Y; Ecelbarger CM; Takahara S; Isaka Y; Rakugi H
    PLoS One; 2016; 11(1):e0147786. PubMed ID: 26807585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control.
    Abdelsaid M; Kaczmarek J; Coucha M; Ergul A
    Life Sci; 2014 Nov; 118(2):268-73. PubMed ID: 24447630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis.
    Wang JG; Zhang M; Feng YQ; Ma CS; Wang TD; Zhu ZM; Kario K
    J Clin Hypertens (Greenwich); 2021 May; 23(5):901-914. PubMed ID: 33609077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of azilsartan medoxomil with chlorthalidone in hypertension.
    Baker WL; Nigro SC; White WB
    Expert Rev Cardiovasc Ther; 2014 Jul; 12(7):791-8. PubMed ID: 24881461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
    Iwanami J; Mogi M; Tsukuda K; Wang XL; Nakaoka H; Ohshima K; Chisaka T; Bai HY; Kanno H; Min LJ; Horiuchi M
    Hypertens Res; 2014 Jul; 37(7):616-20. PubMed ID: 24599018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats.
    Hye Khan MA; Neckář J; Haines J; Imig JD
    Am J Hypertens; 2014 Aug; 27(8):1087-95. PubMed ID: 24598210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodeling after myocardial infarction.
    Nakamura Y; Suzuki S; Saitoh S; Takeishi Y
    Biol Pharm Bull; 2013; 36(8):1326-31. PubMed ID: 23727946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azilsartan attenuates cardiac damage caused by high salt intake through the downregulation of the cardiac (pro)renin receptor and its downstream signals in spontaneously hypertensive rats.
    Komaki H; Iwasa M; Hayakawa Y; Okamoto C; Minatoguchi S; Yamada Y; Kanamori H; Kawasaki M; Nishigaki K; Minatoguchi S
    Hypertens Res; 2018 Nov; 41(11):886-896. PubMed ID: 30209283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro and in vivo pharmacological profiles of a novel angiotensin type 1-receptor blocker, azilsartan].
    Kusumoto K
    Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):236-40. PubMed ID: 22728984
    [No Abstract]   [Full Text] [Related]  

  • 19. Azilsartan, an angiotensin II type 1 receptor blocker, attenuates tert-butyl hydroperoxide-induced endothelial cell injury through inhibition of mitochondrial dysfunction and anti-inflammatory activity.
    Liu H; Mao P; Wang J; Wang T; Xie CH
    Neurochem Int; 2016 Mar; 94():48-56. PubMed ID: 26879328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.
    Kajiya T; Ho C; Wang J; Vilardi R; Kurtz TW
    J Hypertens; 2011 Dec; 29(12):2476-83. PubMed ID: 21986624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.